Obviously this ignores all those who require life long treatment due to other causes of B12 deficiency (of which there are many), thereby potentially causing great harm to the vast majority of their B12 deficient patients
Explore novel modalities such as PROTACs (targeting ACSL4 and Nrf2), gene therapies (e.g., AAV-mediated SLC7A11 overexpression in PT cells), and epigenetic modulators (e.g., m 6 A inhibitors that regulate ferroptosis-related gene expression)
Hsu TM, Noble EE, Liu CM, Cortella AM, Konanur VR, Suarez AN, et al
Similarly, CPGs might explore modular SKUs where, for example, a base drink comes with functional ingredients that consumers add to customise their product based on their own unique body chemistry
"Until these DTC companies generally start getting into the muck of healthcare, they're not going to have a material impact," Parker told Insider